Denmark suspends final form the vacancy of AstraZeneca against the COVID, informs these markets the sanitary authorities. It is first country to abandon completes the pharmacy created by the Pharmacy and Oxford University.
Following the dictates of the European governor and the OMS in favor of his usa, “the holiday campaign in Denmark continued without the vacancy of AstraZeneca“, said the director of the Agencia Nacional de Salud, Søren Brostrøm, at a press conference.
This determination is based on the fact that Copenhagen decides to interrupt its use during five weeks, a lie of the appearance of unusual cases of thrombosis in various European countries. Este jueves finalizaba el plaz de tres semanas decretado a finale van marzo para cto study with the studios of the individual cases.
The European Medicines Agency (EMA) confirms that the benefits of the AstraZeneca vaccine are superior to its risks. Photo: AP
Tanja Erichsen, a senior employee of the Danish Medicines Agency, stated that the authorities “state of accord” with the European Medicines Agency (EMA) that the vaccine is “effective”, but reiterates that, despite the epidemiological situation in Denmark, “it is better” to use the vaccine.
About 150,000 people who receive a dose of this vaccine will be offered another for their second dose, according to authorities.
The suspension of AstraZeneca, of which Denmark has 2.4 million doses, will provoke a retraso of weekly variations in the vacation calendar of this northern country, which pretends to be immunized to all its population in the finals of July.
Denmark has been the first to suspend the March 11 holiday with AstraZeneca, which has decided to close the European Union majority, once again renewing the process under the European Medicines Agency (EMA) ensure that we do not have evidence of direct relationship with cases of thrombosis detected.
Some countries have reserved their embargo on its use for the mayors of 60 years, as is the case in Germany and Sweden, while Norway will announce in a few days that a decision will be taken on the vaccine, also suspended from one month.
In its previous comparison, March 25, the Danish Medicines Agency argued that extension of suspension due to the need to study various cases, even defending the efficacy and safety of the vaccine.
Denmark ha registered a death with this clinical team, which includes a large amount of plaques, clots in blood vessels and hemorrhages; and a case of failure cases with similar syndromes that have not yet been analyzed in March.
With EFE information